Tuesday, May 09, 2023 9:07:37 AM
CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to SYNB1934 for the treatment of phenylketonuria (PKU).
“We are very pleased that SYNB1934 has been granted another regulatory designation, further validating the need for new treatment options for those living with PKU,” said Aoife Brennan M.B. Ch.B., Synlogic President and Chief Executive Officer. “This designation also comes at a pivotal time as we prepare to initiate our Phase 3 trial for PKU – Synpheny-3— in the first half of this year.”
ODD is granted by the FDA to drugs or biologics intended to treat a rare disease or condition, which generally affects less than 200,000 individuals in the U.S. ODD granted therapies entitle companies to development incentives including tax credits for qualified clinical trials, user fee exemptions, and the potential for seven years of market exclusivity after approval.
SYNB1934 has also received Rare Pediatric Disease Designation (RPDD) from the FDA and orphan designation from the European Medicines Agency (EMA).
About SYNB1934
SYNB1934 is an orally administered, non-systemically absorbed drug candidate being studied as potential biotherapeutic for phenylketonuria (PKU). PKU is an inherited rare metabolic disease caused by an inborn error of metabolism that impairs the breakdown of phenylalanine (Phe), an amino acid found in all protein-containing foods. Treatment options for PKU are currently limited, with a majority of individuals with PKU in need of treatment or not adequately responding to treatment. Synlogic designed SYNB1934 to reduce levels of Phe in people with PKU by consuming Phe in the gastrointestinal (GI) tract, using genetic engineering of the well-characterized probiotic E. coli Nissle. Findings to date support the potential for an oral, efficacious, safe, convenient, and flexible treatment option for PKU. SYNB1934 has been granted Rare Pediatric Disease and Orphan Drug designations by the U.S. Food and Drug Administration (FDA) and orphan designation from the European Medicines Agency (EMA).
About Synlogic
Synlogic is the leading company advancing therapeutics based on synthetic biology. Synlogic’s pipeline includ
Recent SYBX News
- Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/19/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 09:37:03 PM
- Form 8-A12B - Registration of securities [Section 12(b)] • Edgar (US Regulatory) • 02/20/2024 10:05:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 09:06:55 PM
- Synlogic Adopts Limited Duration Stockholders Rights Plan • GlobeNewswire Inc. • 02/20/2024 05:15:26 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 09:54:50 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 02/16/2024 09:44:06 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:55:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 09:00:17 PM
- Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update • GlobeNewswire Inc. • 02/08/2024 09:15:00 PM
- Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria • GlobeNewswire Inc. • 02/02/2024 05:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:00:30 PM
- Synlogic Provides Corporate Update and Outlook for 2024 • GlobeNewswire Inc. • 01/04/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/29/2023 09:00:09 PM
- Synlogic Announces Contract with the Air Force Research Lab • GlobeNewswire Inc. • 12/27/2023 12:00:00 PM
- Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023 • GlobeNewswire Inc. • 12/07/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/17/2023 09:00:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/15/2023 12:23:02 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/15/2023 12:22:53 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/15/2023 12:22:51 AM
- Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/09/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 11:44:46 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 11:30:26 AM
- Synlogic Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration • GlobeNewswire Inc. • 11/07/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 11:45:08 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM